Release date: 2024-12-23 13:27:04 Article From: Lucius Laos Recommended: 89
Apellix is a drug used to treat specific types of breast cancer, and its use, storage, and daily precautions are critical for patients.
Interactions between apellix and other drugs may affect its efficacy or increase the risk of adverse effects.
Strong CYP3A inducers, such as rifampicin, rifapentine, phenytoin, carbamazepine, barbiturates, and St. John's wort, can significantly reduce the blood concentration of apellix and reduce the efficacy. Therefore, concomitant use with these drugs should be avoided and, if not, the dose of apelix should be increased appropriately.
BCRP inhibitors may increase the concentration of apellix, thereby increasing the risk of toxicity. Therefore, BCRP inhibitors should be avoided in patients receiving apellix and should be closely monitored for adverse effects if necessary.
Combination with CYP2C9 substrates such as warfarin can reduce plasma concentrations of these drugs, possibly affecting their activity. Therefore, when apellix is used in combination with CYP2C9 substrates, plasma concentrations of CYP2C9 substrates need to be closely monitored.
Proper storage conditions are essential to maintain the stability and efficacy of apellix.
Apellix should be stored in an environment between 20°C and 25°C with a permissible temperature deviation of 15°C to 30°C. Avoid extreme heat or cold environments, freezing may cause changes in drug structure and efficacy.
Choose a dry, well-ventilated place to store apellix to prevent the medicine from getting wet. Changes in humidity can negatively affect the stability of the drug.
Apellix should be kept away from direct sunlight, which may adversely affect the stability of the drug. It should be protected from light or in an opaque container.
Knowing and following the daily precautions for apellix can help patients use the drug safely and effectively.
The recommended dose of apellix is 300 mg (two 150 mg tablets) taken once daily with food. Patients should take the tablets at about the same time each day, swallowing them whole, and should not chew, crush, or separate the tablets.
Patients taking apellix may experience a variety of adverse effects, such as hyperglycemia, diarrhea, rash, etc. Patients should monitor their blood glucose, liver function, and lung condition regularly and report any discomfort to their doctor promptly.
Pregnant and lactating women, people of reproductive potential, children, and older patients should be given special care when using apellix. Pregnant and lactating women should take the drug under the guidance of a doctor, and people of reproductive potential should use effective contraception. Safety and efficacy in children and older patients have not been established and should be used with caution under physician guidance.
Apellix is a drug used to treat specific breast cancers, and its use, storage, and daily precautions must be strictly adhered to. By understanding drug interactions, storing the drug correctly, and following daily precautions, patients can use the drug more safely and effectively, improving treatment outcomes and reducing the risk of adverse effects.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: